retatrutide clinical trials spain Lilly's 'triple G' agonist triumphs in Phase III trial, but AEs unnerve analysts Clinical Trials - ADA Meeting

EASO Congress Proceedings

Y.BradleyD.LiuJ

Immune System Conditions Autoimmune disorders and other conditions affecting immune function could theoretically influence reaction risk

Conclusions Peptide therapies are increasingly used among musculoskeletal patients, yet high-quality evidence supporting clinical efficacy and perioperative safety remains limited

We summarised the current evidence and available recommendations from the ASA and ESAIC to support clinicians in the perioperative management of patients receiving SGLT2 inhibitors, GLP-1RAs and related therapies (Table 2)

10.1016/S0140-6736(08)61206-4 34 DruckerD